-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed says neflamapimod boosts right basal forebrain volume in Lewy body dementia trial

PUBT·04/22/2026 11:30:34
Listen to the news
CervoMed says neflamapimod boosts right basal forebrain volume in Lewy body dementia trial
  • CervoMed presented new placebo-controlled MRI analyses at 2026 AAN Annual Meeting showing neflamapimod improved brain structure and function tied to dementia with Lewy bodies.
  • Results indicated treatment increased basal forebrain volume versus decline on placebo, supporting a potential disease-modifying effect rather than symptomatic benefit.
  • Extension-period imaging also showed stronger functional connectivity in relevant brain networks, aligning with clinical improvement trends reported from trial follow-up.
  • CervoMed plans to incorporate MRI measures into a Phase 3 DLB trial targeted to start later in 2026, subject to financing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220730PRIMZONEFULLFEED9694625) on April 22, 2026, and is solely responsible for the information contained therein.